Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals reported a significant improvement in its second-quarter 2026 financial results, with revenues increasing by 59.5% to $6.41 million and net loss narrowing to $(0.33) million from $(1.24) million in the prior year. The company also successfully completed an equity offering, raising $3.48 million in net proceeds, which substantially boosted its cash position and working capital. Management believes current liquidity is sufficient for the next twelve months.

Sonoma Pharmaceuticals, Inc. has scheduled its 2026 Annual Stockholders' Meeting for Wednesday, September 16, 2026, at 2:00 p.m. MDT, to be held at the company's offices in Boulder, Colorado. Stockholders will vote on the election of Mr. Jerry McLaughlin as a Class III director, an advisory resolution to approve executive compensation for the fiscal year ended March 31, 2026, and the ratification of Frazier & Deeter, LLC as the independent registered public accounting firm for the fiscal year ending March 31, 2027. The Board of Directors recommends a 'FOR' vote on all proposals.

Sonoma Pharmaceuticals, Inc. announced an increase in its At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc., raising the aggregate offering price for common stock sales to $3,641,703. This includes $1,495,830 of common stock previously registered but not yet sold. Since September 26, 2025, the company has sold 173,073 shares for an aggregate purchase price of $574,633 under the agreement.

Sonoma Pharmaceuticals, Inc. (SNOA) filed its 10-K report, detailing significant business updates and product launches. The company has focused on increasing revenues and progressing towards profitability, with revenue growth driven by distribution network expansion, new product introductions, and organic growth. Key developments include the U.S. retail launch of a burn relief hydrogel in CVS and Walmart, the introduction of a new dermatology product line for sensitive skin, and the registration of a facial spray under the FDA's MoCRA. The company also announced new wound cleanser launches, received prestigious seals for its Reliefacyn product, and expanded its product availability in major U.S. retailers and internationally, including the UK and Ukraine.

Sonoma Pharmaceuticals, Inc. is holding a Special Stockholders' Meeting on June 24, 2026, to vote on reincorporating the company from Delaware to Nevada. The Board of Directors recommends approval, citing expected annual savings of approximately $200,000 in Delaware franchise taxes and enhanced protection for directors and officers under Nevada law. The reincorporation is also intended to provide greater corporate flexibility.

Sonoma Pharmaceuticals, Inc. announced the pricing and closing of a public offering, raising approximately $4.0 million in gross proceeds and expecting $3.5 million in net proceeds after expenses. The offering included 2,962,962 units, each consisting of common stock (or pre-funded warrants) and a warrant, priced at $1.35 per unit. The company fully exercised the over-allotment option, issuing a total of 1,650,716 shares of common stock, 1,312,247 pre-funded warrants, and 3,407,404 warrants. Net proceeds will be used for general corporate purposes, including working capital.

Sonoma Pharmaceuticals, Inc. has announced a new Manufacturing and Supply Agreement with Kenvue Brands LLC, effective October 24, 2025. This agreement focuses on the sale of Sonoma's proprietary Microcyn® technology-based products within the United States. The initial term of the agreement extends through March 2027, with a provision for up to two additional one-year extensions upon mutual written consent. This partnership is strategically significant for Sonoma, as it leverages Kenvue's market presence to expand the distribution and availability of its advanced wound care and dermatological products across the U.S. market, potentially driving future revenue growth and strengthening its competitive position.